BofA raised the firm’s price target on Ascendis Pharma (ASND) to $246 from $242 and keeps a Buy rating on the shares after the company announced preliminary FY25 Yorvipath sales in-line with Street estimates. Yorvipath demand trends remained strong to close the year, says the analyst, who adds that a strong Yorvipath launch “continues to be pivotal to our investment thesis.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma Sets 2026 Milestones and Unveils $120 Million Share Buyback
- Ascendis Pharma sees FY25 revenue EUR 720M
- Ascendis Pharma sees FY26 operating cash flow EUR 500M
- Ascendis Pharma announces $120M share repurchase program
- Ascendis Pharma: TransCon CNP/hGH Combo Data De-Risk Achondroplasia Program and Support Higher Target Price and Buy Rating